Roberts Glore & Co. Inc. IL Takes Position in Medpace Holdings, Inc. $MEDP

Roberts Glore & Co. Inc. IL acquired a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,849 shares of the company’s stock, valued at approximately $2,039,000.

Several other institutional investors have also recently modified their holdings of the stock. Johnson Financial Group Inc. acquired a new stake in Medpace during the 2nd quarter valued at $27,000. Geneos Wealth Management Inc. raised its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Elyxium Wealth LLC acquired a new position in shares of Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp purchased a new stake in shares of Medpace in the second quarter valued at $30,000. Finally, Allied Private Wealth LLC purchased a new stake in shares of Medpace in the second quarter valued at $31,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director owned 27,825 shares of the company’s stock, valued at approximately $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Fred B. Davenport, Jr. sold 7,283 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the transaction, the director directly owned 3,798 shares in the company, valued at approximately $2,302,157.70. This represents a 65.73% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 141,639 shares of company stock valued at $83,824,038. 20.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on MEDP shares. Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Robert W. Baird upped their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. BMO Capital Markets upped their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Mizuho raised their price target on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Trading Down 1.0%

NASDAQ MEDP opened at $614.06 on Wednesday. The business’s 50-day moving average price is $556.26 and its 200 day moving average price is $492.77. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The company has a market capitalization of $17.14 billion, a PE ratio of 35.99, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the previous year, the business earned $3.10 EPS. The firm’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest quarterly results were strong: earnings of $4.25 per share exceeded the $3.98 consensus estimate, while revenue rose 17.2% year over year to $707.33 million, ahead of expectations. Management’s fiscal 2026 EPS guidance is $17.25–$17.95. Institutional ownership is also high at approximately 78%, with several large investors adding positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, with a zero-day days-to-cover ratio. Because the figures show no measurable short position, they provide little indication of near-term buying or selling pressure.
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” with an average price target of $584.18, below recent trading levels. BMO Capital Markets raised its target to $600 while maintaining a market-perform rating, and Weiss Ratings upgraded the stock to “Buy.”
• Negative Sentiment: Multiple company insiders recently sold shares. CEO August J. Troendle sold 13,995 shares for approximately $8.74 million on August 21 and another 1,983 shares for about $1.23 million on August 24. CFO Kevin Brady sold 3,400 shares worth roughly $2.13 million, reducing his ownership by 20.95%. Additional director sales were also reported. Although executives retain significant holdings, the concentration of selling can weigh on investor confidence.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.